// App-Quantinova.ai

191 : Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Scott J. Parker

Principal Investigators

  • Gregory Russell Pond

  • Guru Sonpavde

  • Anitha Alex

  • Marta Elise Heilbrun

  • Neeraj Agarwal

Medical Centers

  • University of Utah, Salt Lake City, UT

  • Ontario Clinical Oncology Group, Hamilton, ON, Canada

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Bone metastases

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

  • Orteronel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved